30 closest matches · ranked by relevance
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
Influenza
Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants
Influenza
Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants
Influenza
Primary: Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen — 14.7; 27.9; 6.7; 13.6 Titer
Influenza · Healthy
Primary: Solicted Adverse Events — 8; 12; 13; 14 participants
Influenza A Virus, H5N1 Subtype
Primary: Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A…
Influenza · Influenza Vaccines
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms Overall and by Age Category (18-64 and >64 Years of Age). — 45; 1; 46; 4 Participants
Avian Influenza
Primary: Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by Lot — 16.1; 17.0; 17.0; 128.6 geometric mean titer
Pandemic H5N1 Influenza
Primary: The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 12; 10; 81; 63 Percentages of subjects
Pandemic H5N1 Influenza
Primary: Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 4; 4; 85; 63 Percentages of subjects
Pandemic · Avian Influenza
Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects
Influenza A Subtype H5N1 Infection
Primary: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose — 0; 0; 0; 0 Participants
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Pandemic Influenza
Primary: Assess the Proportion of Subjects in Each Dose Group Achieving Seroconversion and Seroprotection for HI Antibody Titer Through Day 28. — 35.4; 47.4; 37.6; 53.1…
Influenza A Subtype H5N1 Infection
Primary: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29 After Vaccination With the Seasonal…
Influenza
Primary: Number of Seroconverted Subjects Against the H5N1 Strain of Influenza Disease. — 72 Participants
Pandemic H5N1 Influenza
Primary: The Percentages Of Subjects Aged 6 to <36 Months, Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain — 1; 0; 98; 94 Percentages of subjects
Influenza
Primary: Adverse Events by Severity — 20; 8; 25; 8 Participants
Influenza Vaccine
Primary: Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/17/Duck/Potsdam/86/92 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated…
Influenza A Virus, H5N1 Subtype
Primary: Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series — 43; 32; 35; 37 Events
Influenza · Influenza Vaccines
Primary: Number of Subjects Seroprotected for Haemagglutination Inhibition (HI) Antibody Titers Against the H5N1 A/Indonesia Virus Strain. — 175; 184; 201; 0 Subject
Influenza
Primary: Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the…
Avian Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies — 23.3; 19.9; 24.2; 6.0 titer
A/Vietnam/H5N1 Influenza Virus
Primary: Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination. — 34; 41; 34; 34 occurrences
Influenza
Primary: To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43. — 4.64; 4.10; 4.61; 14 Area…
Influenza
Primary: Flu Antibody Titers — 10.65; 10.35; 31.09; 10.35 Titers
Influenza
Primary: The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone. — 83; 70; 9; 76 percentage of…
Influenza
Primary: Number of Subjects With a Hemagglutination Inhibition (HI) Antibody Response to the Vaccine Strain (A/H9N2/Chicken/Hong Kong/G9/97) Associated With Seroconversion 21…
Influenza
Primary: Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age. — 0; 32; 15…
Influenza, Human
Primary: Safety Endpoint 1: Percentages of Subjects With Solicited Local and Systemic Adverse Events (AEs) — 32; 33; 32; 34 Participants